Display Settings:

Format

Send to:

Choose Destination
    Drug Discov Today. 2009 Dec;14(23-24):1150-8. Epub 2009 Sep 28.

    HTS and hit finding in academia--from chemical genomics to drug discovery.

    Source

    Sir James Black Centre, University of Dundee, UK. j.a.frearson@dundee.ac.uk

    Abstract

    The liaison between academia and the pharmaceutical industry was originally served primarily through the scientific literature and limited, specific industry-academia partnerships. Some of these partnerships have resulted in drugs on the market, such as Vorinostat (Memorial Sloan-Kettering Cancer Centre and Merck) and Tenofovir (University of Leuven; Institute of Organic Chemistry and Biochemistry, Czech Republic; and GlaxoSmithKline), but the timescales from concept to clinic have, in most cases, taken many decades. We now find ourselves in a world in which the edges between these sectors are more blurred and the establishment and acceptance of high-throughput screening alongside the wider concept of 'hit discovery' in academia provides one of the key platforms required to enable this sector to contribute directly to addressing unmet medical need.

    PMID:
    19793546
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2814004
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 2
    Figure 1
    Figure 3

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk